Amyotrophic lateral sclerosis (ALS) is the third most common adult onset neurodegenerative disorder worldwide. It is generally characterized by progressive paralysis starting at the limbs ultimately leading to death caused by respiratory failure. There is no cure and current treatments fail to slow the progression of the disease. As such, new treatment options are desperately needed. Epigenetic targets are an attractive possibility because they are reversible. Epigenetics refers to heritable changes in gene expression unrelated to changes in DNA sequence. Three main epigenetic mechanisms include the methylation of DNA, microRNAs and the posttranslational modification of histone proteins. Histone modifications occur in many amino acid residues and include phosphorylation, acetylation, methylation as well as other chemical moieties. Recent evidence points to a possible role for epigenetic mechanisms in the etiology of ALS. Here, we review recent advances linking ALS and epigenetics, with a strong focus on histone modifications. Both local and global changes in histone modification profiles are associated with ALS drawing attention to potential targets for future diagnostic and treatment approaches. (Translational Research 2019; 204:19À30) Abbreviations: 3 0 -UTR; 3 0 -untranslated region; ALS; amyotrophic lateral sclerosis; AMPA; a-amino-3-hydroxy-5-methyl-4-isoxazole propionic Acid; C9orf72; chromosome 9 open reading frame 72; DRE; dipeptide repeat expansion; FTD; frontotemporal dementia; FUS; fused In sarcoma; HAT; histone acetyltransferase; HCP; high-CpG-density promoter; HDAC; histone deacetylase; miRNA; microRNA; NFL; low-molecular weight neurofilament; PTM; post-translational modification; PRMT; protein arginine N-methyltransferase; SMN; survival of motor neuron; RISC; RNA-induced silencing complex; SOD1; superoxide dismutase 1; SIRT; sirtuin; SUV39H; suppressor of variegation 3-9 homologue 1; TDP-43; TAR DNA-binding protein 43
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the selective loss of both upper and lower motor neurons. 1 As motor neurons in the spinal cord, brain, and brainstem weaken, skeletal muscular atrophy spreads through the patient. 2 Depending on the type of motor neurons affected, ALS can present itself clinically as either limb onset-manifesting as muscle weakness or bulbar onset-manifesting as speech impediments. 1 Prognosis is poor and quality of life is significantly reduced as most patients succumb to the disease within 3 years of diagnosis. 3 There is no cure for ALS and the only 2 Food and Drug Administration approved drugs, Rilutek (riluzole), and Radicava (edaravone), fail to stop progression of the disease. [4] [5] [6] ALS is classified into 2 categories: familial and sporadic. Familial ALS represents about 10% of all cases, where the disease can be attributed to a particular gene mutation running in families. 7 Sporadic cases, on the other hand, represent the remaining 90% for which there is no family history of the disease. Numerous genes have been associated to ALS. 8 Some of these include superoxide dismutase 1 (SOD1), chromosome 9 open reading frame 72 (C9orf72), Fused in Sarcoma (FUS), and TAR DNA-binding protein . 9 Both familial and sporadic cases share similar pathology; the overwhelming majority of cases present neuronal TDP-43 protein aggregates. 10 Interestingly, not only neuronal cells are affected by these mutations. Glial cells harboring SOD1 mutations have been shown to drive motor neuron degeneration in experimental models. [11] [12] [13] [14] More specifically, microglia bearing a SOD1 mutation caused motor neuron degeneration in otherwise healthy mice, 15 and human derived motor neurons cocultured with these microglia showed signs of motor degeneration as well. 16 Nevertheless, the true origin of ALS remains obscure. Therefore, there is an urgent need to understand the pathogenesis of ALS in order to develop new treatment options. Aberrant epigenetic mechanisms linked to ALS are beginning to be discovered. These are attractive therapeutic targets as they are pharmaceutically accessible and largely reversible. 17 Epigenetics refers to heritable alterations in gene expression without modification to the genome. 18 Three main epigenetic mechanisms include DNA methylation, microRNAs (miRNA), and histone posttranslational modifications (PTMs). DNA methylation takes place on the 5' carbon on cytosine bases and is involved in transcription regulation. 19 DNA methylation at enhancers is key in determining cell line fate. 20 Hypermethylation at gene promoters is generally found to silence gene expression, while methylation in the coding region can increase transcription. DNA methylation is a crucial rate-controlling step that occurs in genomic regulatory regions during transcription, making it detectable and possibly even reversible for treatment purposes. 21 miRNAs are key regulators of gene expression. 22 miRNAs are noncoding short pieces of RNA, containing approximately 22 nucleotides that generally bind to the 3 0 -untranslated region (3 0 -UTR) of mRNA, causing degradation of the mRNA and translational silencing.
Histones are proteins which package and organize cellular DNA. 23 One hundred forty-six bases of DNA coil around 2 H2A/H2B dimers and 1 H3/H4 tetramer. The histone N-terminal tails are heavily modified with a multitude of chemical moieties, including monomethylation, dimethylation, and trimethylation, acetylation, phosphorylation, SUMOylation, and ubiquitination occurring in a variety of residues. 24 Histone post-translational modifications (PTMs) play an important role in gene regulation by controlling the accessibility of DNA to the transcriptional machinery. Initially, histone PTMs were thought to only impact gene transcription by controlling how tightly DNA wraps around the histones. For example, histone acetylation on lysine residues lowers the positive charge on histones and the strength of interaction with the negatively charged DNA backbone favoring gene transcription. Conversely, hypoacetylation is associated with transcriptional silencing. [25] [26] [27] [28] More recently, it has been established that these modifications actually comprise a "histone code" that other proteins can "write," "erase," and "read." 29, 30 Histone PTMs can also affect one another through "cross talk." 31 For example, the phosphorylation of Serine 10 on Histone H3 (H3S10ph) promotes acetylation on Lysine 16 on Histone H4 (H4K16ac) and also inhibits trimethylation on Lysine 9 on Histone H3 (H3K9me3). 32, 33 While, a thorough understanding of the underlying mechanisms resulting in ALS have yet to be reached, recent evidence shows that alterations in the epigenetic landscape might contribute to disease pathology. Here, we review recent evidence showing a link between ALS and epigenetics. While, we incorporate exciting findings featuring DNA methylation and miRNA mechanisms, we mostly focus on recent advances linking histone PTMs to ALS.
DNA METHYLATION IN ALS
DNA methylation on cytosine bases is one the most studied epigenetic factors in neurodegenerative diseases and ALS. 17 In postmortem spinal tissue from sporadic ALS patients, there are global alterations in DNA methylation and hydroxymethylation. 34 Not surprisingly, many of the genes that were hypomethylated or hypermethylated showed corresponding changes in decreasing or increasing gene expression. Interestingly, these genes were largely involved with the immune and inflammatory responses. Other reports link DNA methyltransferases (Dnmt3a), a de novo DNA methyltransferase, to ALS phenotypes. 20, [35] [36] [37] Mice lacking Dnmt3a are hypoactive, underperformed on tests of neuromuscular function and motor coordination and had decreased numbers of motor neurons akin to SOD1 mouse models of ALS. 35 Interestingly, Dnmt3a is required for the development of motor neurons in vitro. 20 Moreover, apoptosis observed in NSC34 cells treated with camptothecin and in wild-type mice with unilateral nerve avulsion was driven by increased activity of Dnmt3a, Dnmt1 À a maintenance DNA methyltransferase À and increased levels of 5-methyltransferase. 36 Remarkably, Dnmt inhibition with RG108, a DNA methyltransferase inhibitor, blocked apoptosis in both cultured neurons and mice. In agreement, levels of Dnmt1, Dnmt3a, and 5-methylcytosine are upregulated in the brain and spinal cords of ALS patients. 36 Furthermore, Dnmt3a was found in the mitochondria of the central nervous system and skeletal muscle of adult wild-type mice, but was significantly reduced in the mitochondria of ALS SOD1 mice. 37 Counter intuitively, there was also an increase in mitochondrial DNA methylation in the SOD1 mice, including at the 16S ribosomal RNA gene, which encodes for the mitochondrial 16 S rRNA subunit. The SOD1 mice also displayed increased mitophagy-the degradation of the mitochondria by way of autophagy, which contributed to neuronal degeneration.
Recently, genome-wide association studies discovered differentially methylated genes involved in pathways important to ALS and frontotemporal dementia (FTD)-ALS. 38 In the FTD-ALS subgroup, pathway analysis revealed 3 gene sets displaying enriched DNA methylation; among these is the Meissner Brain HCP with H3K4me3 and H3K27me3 gene set. This gene set contains genes with high-CpG-density promoters (HCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3), 39 suggesting that both DNA methylation and histone PTMs are important in the progression of FTD-ALS. Interestingly, H3K4me3 and H3K27me3 are associated with neurological function. 40 For an in-depth examination of the links between DNA methylation and ALS, we direct the reader to a thorough review by Martin & Wong. 41 miRNA AND ALS miRNAs are an epigenetic mechanism that reduce gene expression by binding argonaute 2 and forming the RNA-induced silencing complex (RISC).
42, 43 The complex then binds the 3 0 -UTR of a specific mRNA, and degrades it if there is an extensive match between the mRNA and miRNA or, if there is a less extensive match, just binds the mRNA repressing expression of the bound transcript. [44] [45] [46] miRNAs are associated with neurodegenerative diseases such as alzheimer's disease, 47 parkinson's disease, 48 and huntington's disease. 49 Several lines of evidence link ALS to miRNA dysregulation. 17, 50 For instance, there is a global decrease in miRNA levels in the spinal cords of ALS patients. 51 The levels of miRNAs were compared to healthy controls and 90 miRNAs were found to be dysregulated. These miRNAs had mRNA targets involved in cell death, immune response, and brain development that may possibly contribute to ALS etiology. Some of these included upregulation of miR-155 and miR-142. These miRNA target ubiquilin 2 (UBQLN2), the RNA-binding protein Fox-1 (RBFOX1), and reelin (RELN), a protein secreted by certain neurons to guide neuronal migration. 52 All of these genes have been associated with neurodegeneration. 51 Interestingly, genes involved with immune response were also found to be dysregulated in ALS patients with aberrant DNA methylation patterns. 34 This suggests a role for epigenetics contributing to cellular demise caused by inflammation in ALS. Furthermore, TDP-43 overexpression in AinV15 mouse embryonic stem cells inhibited the endogenous activity of miRNAs regulating the genes EIF2C4/AGO4.
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These genes are members of the RNA-induced silencing complex-the ribonucleoprotein complex that is responsible for translational silencing by cleaving miRNA and complementary mRNAs-and have been found to be dysregulated in ALS. 53, 54 Moreover, a large number of miRNAs were differentially expressed in the spinal cord motor neurons of sporadic ALS patients. 55 Functional analysis revealed the some of the upregulated miRNAs could bind to the 3'-UTR of low-molecular weight neurofilament (NFL), 55 an important cytoskeleton protein involved in mitochondrial transport in motor neurons, 56 leading to a decrease in NFL mRNA levels. Interestingly, protein levels of NFL are found to be lowered in ALS. [57] [58] [59] Additionally, FUS disrupts the circuitry between miR-409 and miR-495 in motor neurons derived from embryonic mouse cells with a FUS knockin mutation. 60 miR-409 and miR-495 regulate the expression of ionotropic glutamate receptor 2 (Gria2), which encodes for a subunit of a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor. The upregulation of these miRNAs led to a decrease in Gria2 mRNA. The authors validated that miR-409 and miR-495 bind the 3 0 -UTR of Gria2. Furthermore, FUS stabilizes the interactions between the miRNA and their target, leading to decreased Gria2 expression. 60 Gria2 alteration has been previously implicated in motor neuron degeneration via alterations in Ca 2+ homeostasis leading to excitotoxicity. [61] [62] [63] In light of all these alterations, miRNA profiling has been proposed as a potential biomarker panel for neurodegeneration and ALS Table I . 50 For example, microarray analysis of leukocytes from sporadic ALS patients compared with healthy controls revealed 8 miRNAs that were dysregulated. 64 Of these miRNA, only miR-338-3p was upregulated, and interestingly it has been previously found to be dysregulated in the brains of ALS patients. 65 A study of skeletal tissue from SOD1 G93A mice revealed that miR-206 was upregulated, and confirmed to also be upregulated in the plasma of ALS patients. 66 Similarly, comparison of circulating miRNAs in plasma form sporadic ALS patients and healthy controls revealed 9 dysregulated miRNAs, 3 of which were upregulated. 67 Two of these miRNAs, has-miR-46469-5p and has-miR4299, were confirmed to be respectively upregulated and downregulated in a larger ALS patient cohort. Interestingly, both of these miRNAs target EPHA4, a gene that is has been associated with ALS in animal models.
68 EPHA4 contributes to brain development and neuronal migration, much like RELN discussed above. 51 These results suggest epigenetic mechanisms may be contributing to ALS pathology through alterations in development. Furthermore, a number of miRNAs have been found to be dysregulated in the leukocytes of ALS patients. 69 Specifically, AAKT, which encodes for miR-338, is upregulated, while DNM2, which encodes for miR-638, is downregulated. Both of these miRNAs have been found to be involved in other neurodegenerative diseases, such as FTD and hereditary spastic paraplegia. 70, 71 Overall, miRNAs appear to play an important role in the pathology of ALS and show promise as robust diagnostic biomarkers.
HISTONE MODIFICATIONS AND CHROMATIN REMODELING ENZYMES IN ALS
Compared to other diseases, the study of epigenetic mechanisms involved in ALS is just in its beginning stages and relatively few studies examining the association between epigenetics and the disease have been carried out. While most investigations have focused in DNA methylation, recent evidence has linked aberrant changes in histone PTMs levels to neurodegenerative disease and ALS. 7, 17, 72 Remarkably, many enzymes responsible for installing or removing histone modifications have also been associated with ALS Table II. For instance, histone acetyltransferases (HATs) and histone deacetylases (HDACs) are responsible for the addition and removal of acetyl groups on histones, respectively. There are 2 classes of HDACs that are Zn 2+ dependent including HDACs. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] A third class, Sirtuins (SIRT), [1] [2] [3] [4] [5] [6] [7] are NAD + dependent. 73 HDACs are drug targets for the treatment of many diseases, including cancer, inflammatory disease, and pulmonary disease. [74] [75] [76] Correspondingly, there are a variety of kinases responsible for phosphorylating histones, including aurora B kinase and AMP kinase. 77 Lastly, many histone methyltransferases are responsible for the deposition and removal of methyl groups on lysine and arginine residues on histones. 78 These enzymes can be specific to monomethylation, dimethylation, and trimethylation, as well as symmetric and asymmetric methylation. 79 Histone acetylation, HATs, and HDACs. Histone acetylation has been repeatedly associated with ALS. In a FUS overexpression model in HeLa cells, FUS binds to and inhibits CBP/p300 HAT at a specific gene promoter and causes hypoacetylation near the CCND1 gene. 80 This causes reduced expression of CCND1, which encodes for cyclin D1, a protein required for progression through the cell cycle. 81 HeLa cell models have been repeatedly used in ALS research. [82] [83] [84] Evidencing another link between histone acetylation and ALS, ELP3 À a protein with HAT activity was linked to motor neuron degeneration in ALS in a microsatellite-based genetic association study. 85 In zebra fish embryos, ELP3 knock down with antisense RNA leads to motor neuron degeneration in a dose dependent manner. 85 ELP3 acetylates lysine 14 on histone H3 (H3K14) and lysine 8 on histone H4 (H4K8). 86 Interestingly, mutagenesis screening in Drosophila revealed that ELP3 is critical for neuronal communication and survival. 85 These results support a role for histone hypoacetylation in ALS pathology. In fact, ELP3 directly regulates heat shock protein 70 (HSP70) expression by acetylation of histones H3 and H4 in yeast; 87 hence, ELP3 defects could result in motor neuron degeneration through a decrease in the transcription of HSP70. 81 Recently, we characterized global histone acetylation levels in yeast ALS proteinopathy models. 72 Many cellular pathways are conserved from yeast to humans. 88, 89 Furthermore, yeast recapitulate the cellular toxicity and 90, 91 In fact, yeast models have enabled identification of common ALS genetic risk factors. 92 Yeast overexpressing human FUS showed significantly decreased levels of acetylation on lysine 14 and lysine 56 on histone H3 (H3K14 and H3K56). 72 These histone PTM are conserved in humans. H3K14ac and H3K56ac are both involved in the DNA damage checkpoint activation. [93] [94] [95] Furthermore, H3K14ac is also found at the promoter of actively transcribed genes. 96 Interestingly, yeast overexpressing FUS had overall decreased RNA levels, suggesting that histone hypoacetylation leads to reduced transcription.
72 Surprisingly, an analogous TDP-43 yeast proteinopathy model did not display the same decrease in histone acetylation, but instead revealed hyperacetylation on lysines 12 and 16 on histone 4 (H4K12 and H4K16). H4K12ac is a modification localized on gene promoters and is associated with gene activation.
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H4K16ac is a particularly interesting modification because it is associated with both gene expression and repression. 98, 99 Remarkably, each proteinopathy displayed its own distinct histone modification landscape. Puzzlingly, while both of these models share protein aggregation and cytotoxicity features, FUS and TDP-43 overexpression resulted in histone hypoacetylation and hyperacetylation, respectively. This suggests that each proteinopathy and corresponding histone PTM profile may be leading to ALS in unique ways.
In addition to changes on histone acetylation, HDACs have been thoroughly implicated in ALS. 100 For instance, deletion of Set3-a member of a histone deacetylase complex, homolog to the human protein ASH1-was found to suppress the toxicity of TDP-43 inclusions in a yeast model. 101 Moreover, postmortem analysis of brains and spinal cord tissue derived from ALS patients showed a decrease in HDAC 11 mRNA and an increase of HDAC 2 mRNA. 102 Furthermore, HDAC 1 has been found to mislocalize to the cytoplasm in a FUS knock-in mouse model. 103 Curiously, post-translational modification on the histone modifiers themselves appears to be important. Phosphorylation of serine residues in HDAC1 controls its subcellular localization, and HDAC1 accumulation in the nucleus was neuroprotective in a mouse model. 104 Further evidence for HDAC perturbations in ALS comes from SOD1 mouse models. SIRT1 levels are decreased in neurons and increased in muscles of mice expressing mutant SOD1, while SIRT2 mRNA levels decrease in motor neurons in the same model. 105 In NSC34 and HEK293 cells as well as mice expressing wild type and mutant SOD1 G93A , HDAC6 knock-down induced SOD1 aggregation resulting in increased motor neuron loss. 106 In the same mice model, HDAC6 levels drop as ALS symptoms appear and then plummet as the disease progresses. 107 Interestingly, in this mouse model HDAC6 overexpression prolongs life span and delays motor neuron decay by inducing fusion of autophagosomes to lysosomes and promoting autophagy. 107 HDAC cofactors also appear to play a role in disease. 108 For example, loss of NAD + , a SIRT cofactor, contributes to neurodegeneration. 109 Furthermore, the loss of intracellular nicotinamide phosphoribosyltranferase-the rate limiting enzyme in NAD + synthesis leads to motor neuron degeneration in mice, where the gene was knocked out. 110 Increased activity of PARP1 has been observed to deplete NAD + pools, and contributes neurotoxicity. 111 Interestingly, silencing of Parp1 is neuroprotective in a mouse model of cerebellar ataxia, 111 and it is a possible therapeutic target for neurodegeneration.
HDAC inhibition has arisen as a promising therapeutic in various ALS models. Treatment with trichostatin A, an HDAC inhibitor, ameliorated motor neuron degeneration in a SOD1 mouse model. 112 In motor neurons derived from ALS patients, pharmacological inhibition and genetic silencing of HDAC6 reverses axonal transport defects caused by mutant FUS. 113 Furthermore, HDAC inhibition with 4-PB increased motor function and neuroprotection in transgenic ALS mice. 114 Interestingly, treatment with sodium phenylbutryate, a general HDAC inhibitor, extended survival in SOD1 G93A ALS mouse model, 115 and its effect is increased when combined with an antioxidant or Riluzole. 116, 117 Phenylbutyrate has shown to be safe and increase histone acetylation levels in ALS patients. 118 Perplexingly, loss of HDAC function and is related to disease in some models, [112] [113] [114] [115] while HDAC inhibition is neuroprotective in others. 103, [105] [106] [107] Future studies will potentially reconcile these seemingly opposite landscapes and elucidate their contribution to ALS pathways.
Histone methylation and methyltransferases. Lysine and arginine methylation have varying effects on gene expression. Generally, monomethylation is associated with transcription activation, while trimethylation is associated with transcription repression. 119 Recent evidence has linked trimethylation of lysine residues on H3 and H4 with loss-of-function toxicity in ALS patients with dipeptide repeat expansions (DRE) in C9orf72.
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There is an increase in H3K9me3, H3K27me3, and H4K20me3 levels around the DREs sequence in brain tissue from ALS patients compared to healthy controls. These histone PTMs are strongly associated with gene silencing. 119 Decreased levels of C9orf72 mRNA in patients support a loss-of-function toxicity model. 120 Interestingly, treating fibroblasts derived from patients bearing C9orf72 mutations with a histone demethylating agent reduced trimethylation levels near DREs and restored C9orf72 mRNA levels. 120 In yeast models of ALS, we observed distinct histone methylation profiles for TDP-43 and FUS proteinopathies. 72 Specifically, FUS overexpression is associated with decreased levels of asymmetric dimethylation on arginine 3 on histone H4 (H4R3me2asym), while TDP-43 overexpression is associated with decreased levels of trimethylation on lysine 36 on histone H3 (H3K36me3). H34Rme2asym is associated with increased gene expression, 121 whereas H3K36me3 is linked to transcriptional repression by serving as a docking site for HDACs and promoting deacetylation. 122, 123 As for acetylation, these results highlight that different proteinopathies can have unique effects on epigenetic mechanisms. H4Rme2 is linked to H3K14ac, 124 which also decreased in this FUS model, underscoring cross talk between these 2 modifications.
Protein arginine N-methyltranserfase 1 (PRMT1) is a methyltransferase that has been positively implicated in ALS. PRMT1 is responsible H4R3me2asym, which promotes histone acetylation and gene transcription. 125 In a FUS R521C mouse model of ALS, overexpression of PRMT1 was found to rescue neurite growth after oxidative stress. 126 The same study showed that PRMT1 activity is inhibited by interaction with FUS as a stable complex of FUS/PRMT1/Nd1-L mRNA is formed. Nd1-L is an actin-stabilizing protein and is underexpressed in this model. Furthermore, in agreement with our FUS yeast model results, 72 loss of PRMT1 function-due to FUS mislocalization-led to the reduction of asymmetric dimethylation of arginine 3 on histone H4 (H4R3me2asym) causing a drop in the acetylation of histone H3 on lysine 9 and 14, ultimately leading to transcriptional silencing. 127 Histone phosphorylation and ubiquitylation. Phosphorylation on serine, threonine, and tyrosine histone residues plays an important role in gene expression, transition through the cell cycle and DNA damage repair. 77 Histone phosphorylation and many enzymes responsible for it have been implicated in ALS and other neurodegenerative diseases. 128 For example, loss of FUS through RNA interference leads to decreased cell proliferation and an increase in H3 phosphorylation in NSC-34 and HEK-293T cells. 129 This coincides with altered expression of genes involved in cell cycle regulation, cytoskeletal organization, oxidative stress, and energy homeostasis, and may point to a loss-offunction mechanism for FUS mutants related to ALS.
In a FUS overexpression model in yeast, we discovered a reduction in phosphorylation levels on threonine 129 on histone H2B (H2BT129ph). 72 In yeast, reduced H2BT129ph is associated with decreased gene expression. 130 In the same model, we identified a profound decrease in the levels of phosphorylation on serine 10 on histone H3 (H3S10ph). H3S10ph is associated with active gene expression. 77 Furthermore, H3S10ph promotes acetylation of histone H3 on lysine 14 (H3K14ac) in yeast, 131 suggesting histone cross talk may play an important role in disease processes. Interestingly, Ilp1, the yeast homologue of human aurora B kinase, can phosphorylate both H3S10 and H2BT129.
These results suggest aurora B kinase might be involved in ALS pathology.
Increased R-Loops (DNA-RNA triple helixes) and DNA double-strand breaks were observed in vitro and in the spinal tissue of ALS patients with mutations in C9orf72.
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This damage was associated with dipeptide repeats in C9orf72 causing an accumulation of P62 and impaired H2A ubiquitylation at lysine 119 (H2AK119ub1). P62 is an autophagy protein related to ALS, and its accumulation inhibits RNF168, the enzyme responsible for ubiquitylation on H2A. 133 Reduced ubiquitylation impaired ATM signaling, an important pathway involved in DNA damage repair, 134 and perturbed DNA double-strand break repair. One issue that arises whenever discussing histone modification is causality. 135 Are histone modifications a consequence of neurodegenerative proteinopathies or do changes in modifications lead to disease? Further research into how ALS-associated proteins interact with histone "writers," "erasers," and "readers," and perhaps even the histone PTMs themselves is necessary to definitively answer this question. This may still be an emerging field with a number of questions yet to be answered, but as discussed above for HDACs inhibitors, drugs targeting histone modifiers are effective treatments in ALS models. [112] [113] [114] [115] [116] [117] [118] Thus, causality might ultimately be inconsequential, as pharmaceutical intervention targeting epigenetic features of ALS would alleviate disease outcomes. A number of histone modifications are associated with ALS, and each enzyme responsible for adding, removing, or reading these modifications is a potential drugable target. Aside from HATs and HDACs, further research into chemical modulation of histone kinases, phosphorylases, methyltransferases, and demethylases is needed. For example, inhibitors of protein phosphatase 1 and 2, responsible for removal of H3S10ph, 136, 137 as well as inhibitors of JMJD6, a Jumonji-domain-containing protein reported to demethylate H4R3me2, 138 may be useful therapeutic targets for ALS.
Chromatin remodeling enzymes. Eukaryotic DNA is packed into chromatin. DNA wraps around histones to form nucleosomes, the basic units of chromatin. Chromatin structure affects gene expression by controlling the accessibility to DNA. 139 Transcriptionally active chromatin is termed euchromatin and while transcriptionally silent chromatin is referred to as heterochromatin. 24, 140 Chromatin plays a key role in nearly all eukaryotic DNA-templated processes such as mitosis, DNA repair, and transcription. Some histone PTMs directly contribute to chromatin structure. For instance, H4K16ac inhibits the formation of heterochromatin, 141 while H3K9me3 binds heterochromatin protein 1 promoting chromatin compaction. 33 Additionally, enzymes that target histone PTMs can also play a role in chromatin compaction. For example, the HDAC SIRT1, which deacetylates H4K16, also has the ability to dephosphorylate the active site of the methyltransferase suppressor of variegation 3-9 homologue 1 (SUV39H1), increasing its activity and consequently increasing H3K27me3 levels and promoting chromatin compaction. 142 Aside from enzymes that directly affect histone PTMs, there a number of ATP-dependent chromatin remodeling enzymes that move, eject, or otherwise restructure histones to control chromatin structure. 143, 144 Some of these have been associated to ALS and neurodegenerative disease. For example, in a TDP-43 overexpression Drosophila model, the chromatin-helicase-DNA binding protein Chd1 was inhibited by TDP-43, which in turn inhibited the stress response needed for neuronal survival. 145 Chd1 alters gene accessibility by modifying chromatin structure. 146 This loss of Chd1 function led to decreased expression of protective genes, such as the proteins involved in the REST and Hsp70 pathway. Correspondingly, upregulation of Chd1 was found to be neuroprotective. The human orthologue of Chd1, CHD2, physically interacted with TDP-43 and was significantly reduced in the temporal cortex of patients with ALS. 145 Therefore, at least some of toxicity associated with TDP-43 seems to be caused by the reduced expression of protective genes caused by chromatin rearrangement.
POLR2A, a subunit of the carboxy-terminal domain of RNA Polymerase II, reads modifications specifying the recruitment of factors that regulate transcription, mRNA processing, and chromatin remodeling. 147 Arginine 1810 of POLR2A is symmetrically dimethylated by protein arginine methyltransferase 5 (PRMT5) and this modification recruits the Tudor domain of survival of motor neuron. Survival of motor neuron interacts with senataxin, which is sometimes mutated in ALS. 148 Perturbations in this pathway lead to the formation of R-loops, genomic instability and premature transcription termination causing neurodegeneration. 147 Furthermore, RNA Polymerase II, as well as TDP-43 and FUS, colocalize with gH2AX (a histone H2A isoform phosphorylated on serine 139).
149 gH2AX is a sign of DNA double-strand breaks.
150 gH2AX colocalization with TDP-43 and FUS suggests these proteins may have a role in double-strand break repair. DNA double-strand breaks may be harder to resolve when FUS or TDP-43 mislocalize from the nucleus, promoting neurodegeneration and suggesting a loss-of-function toxicity model for these 2 ALS-associated proteins. A summary of the histone and chromatin modifying enzymes implicated in ALS is presented in Table II .
CONCLUSIONS
Mounting evidence highlights the role of epigenetic mechanisms in ALS pathology. DNA methylation, miRNAs, and histone PTMs have distinct contributions to neurotoxicity. The evidence reviewed here reveals distinct DNA methylation patterns and dysregulation of miRNAs are associated with ALS. Although understudied, perturbations in the levels of histones modifications lead to alterations of gene expression and can contribute to the neurodegeneration. Remarkably, these alterations seem to be distinctly connected to different proteinopathies. Chromatin remodeling enzymes, which do not specifically impact histone modifications, also contribute to ALS pathology by reducing expression of survival genes and impairing DNA break repair. Though exact knowledge of how the different epigenetic mechanisms, in particular histone PTMs, affect ALS development and progression is still lacking, we are beginning to characterize them and realizing their potential importance in understanding ALS. Although much work remains to elucidate causal relationships and mechanisms linking histone PTMs and neurodegeneration, these findings highlight the critical need for the inclusion of epigenetics in neurodegenerative disease research. Remarkably, some of these altered epigenetic profiles can be detected in blood, and may become useful biomarkers for diagnosis and assessment of disease or treatment progress. We expect discoveries to come in the next decade will take us beyond establishing the links between ALS and epigenetics and move towards elucidating the precise epigenetic mechanisms associated with disease processes and specific symptoms. Pinpointing how epigenetic changes relate to disease can potentially lead to novel diagnostic and therapeutic tools for ALS and other neurodegenerative diseases. 
